Gennex Laboratories Ltd. (GENNE): Gennex Laboratories Share Price Rises 10.09% Today; Micro Cap Stock Gains Attention

Gennex Laboratories Ltd. traded at Rs 12.88, up 10.09% today, taking its market capitalisation to Rs 285.95 crore and placing the micro cap stock among notable gainers.

Gennex Laboratories Share Price moved higher to Rs 12.88 on 21 August 2026, up 10.09% from the previous close of Rs 11.70, giving the Healthcare stock a market capitalisation of Rs 285.95 crore. The move matters because it placed the company among the notable micro cap gainers in today’s session and qualified it under the price rise screen tracked by Univest.

For investors looking at Gennex Laboratories Share Price Today, the verified data confirms a strong same-day gain backed by active trading on BSE, where total volume stood at 28,87,678 shares and turnover reached Rs 3.72 crore. The stock traded in an intraday band of Rs 11.32 to Rs 12.89 after opening at Rs 11.77, which shows that buying interest remained visible through most of the session.

Why is it trending in Stock Market Today searches? The supplied data establishes the price event and the scale of the move, but it does not establish a company-specific catalyst. What it does show is that Gennex Laboratories Share Price rose sharply enough to stand out in Share Market Today screens, while valuation and profitability data give investors more context. Gennex Laboratories currently trades at a P/E ratio of 14.66, a P/B ratio of 1.25, ROE of 10.71 and ROCE of 13.24, placing the stock in an interesting position relative to its Pharmaceuticals & Drugs industry benchmark. For readers tracking Gennex Laboratories Stock News on Univest, the next step is to assess whether today’s price action is supported by business and sector metrics rather than by price movement alone.

Gennex Laboratories Ltd. (GENNE) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 12.88
Previous Close	Rs 11.7
Today's Change	+Rs 1.18 (+10.09%)
Day Open	Rs 11.77
Day High	Rs 12.89
Day Low	Rs 11.32
Current Volume (BSE)	28,87,678
BSE Traded Volume	28,87,678
Combined NSE + BSE Volume	28,87,678
Turnover	Rs 3.72 crore
Market Capitalisation	Rs 285.95 crore
Market Cap Category	Micro Cap

Gennex Laboratories Ltd. (GENNE) traded at Rs 12.88. versus the previous close of Rs 11.7, a rise of 10.09%. The stock opened at Rs 11.77, reached Rs 12.89, touched Rs 11.32. Reported volume was 28,87,678.

Gennex Laboratories Ltd. (GENNE) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 285.95 crore
P/E Ratio	14.66x
P/B Ratio	1.25x
ROE	10.71%
ROCE	13.24%
EPS	Rs 0.8
Dividend Yield	0%

Gennex Laboratories Ltd. was valued at a P/E ratio of 14.66x, a P/B ratio of 1.25x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 10.71% and ROCE of 13.24%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 0.8, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Gennex Laboratories Share Price is drawing attention today, but the financial ratios add important context beyond the headline move. At a market capitalisation of Rs 285.95 crore, the company sits well inside the smaller end of the listed Pharmaceuticals & Drugs space. Its P/E ratio stands at 14.66 and its P/B ratio is 1.25, which immediately places valuation in focus because both ratios can be compared with the wider industry benchmarks supplied for the same industry.

On profitability, Gennex Laboratories reports return on equity of 10.71% and return on capital employed of 13.24%. Those figures suggest the business is generating positive returns on shareholder equity and operating capital, though the numbers are more useful when read against peers and sector medians rather than in isolation. The stock’s EPS is Rs 0.80, which indicates the earnings attributable to each share based on the supplied data. For investors checking Gennex Laboratories Fundamental Analysis, EPS matters because it directly connects the share price with earnings through the P/E multiple.

The dividend yield is 0, which means the current data does not point to a cash yield component in the stock’s appeal at this stage. That leaves valuation and return ratios as the more immediate analytical anchors. The P/B ratio of 1.25 is notable because it implies the stock is trading only modestly above its accounting net worth relative to many pharma names that command materially higher book multiples. In practical terms, that can make Gennex Laboratories Share Price News relevant not only for momentum screens but also for valuation-based stock analysis.

Univest would also note that market capitalisation by itself does not indicate quality; it only reflects company size at the current market price. The more useful takeaway is that Gennex Laboratories combines a relatively modest earnings multiple with positive ROE and ROCE. That mix does not by itself justify the move, but it does provide a measurable framework for investor attention. To judge that framework properly, the stock needs to be viewed against its industry and peer set.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	14.66x
Benchmark Median P/E	25.39x
Benchmark Average P/E	39.57x
Benchmark P/E Range	2.98x to 363.23x
Company P/B Ratio	1.25x
Benchmark Median P/B	1.86x
Company ROE	10.71%
Benchmark Median ROE	10.49%
Company ROCE	13.24%
Benchmark Median ROCE	12.97%
Company Market Capitalisation	Rs 285.95 crore
Benchmark Median Market Cap	Rs 138.88 crore

Gennex Laboratories Ltd. (GENNE) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Gennex Laboratories Ltd. (GENNE) has a P/E ratio of 14.66x, which is below the benchmark median of 25.39x, a difference of -42.26%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Gennex Laboratories Ltd. (GENNE) has a ROE of 10.71%, which is above the benchmark median of 10.49%, a difference of +2.1%. Gennex Laboratories Ltd. (GENNE) has a ROCE of 13.24%, which is above the benchmark median of 12.97%, a difference of +2.08%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Gennex Laboratories Share Price is best understood in the context of the Healthcare sector and, more specifically, the Pharmaceuticals & Drugs industry. Within the supplied benchmark scope of the same industry, covering 136 companies, the stock’s valuation and return profile sits in a distinct position relative to median and average sector readings.

The most striking comparison is on earnings valuation. Gennex Laboratories trades at a P/E of 14.66, while the industry benchmark median P/E is 25.39 and the average is 39.57 across 105 companies with available P/E data. The benchmark range is wide, from 2.98 to 363.23, but even within that spread the company’s multiple sits below both the median and average. That makes Gennex Laboratories Share Price relevant for investors screening for lower-multiple pharma names, at least on the supplied earnings metric.

Book value valuation also looks comparatively restrained. The company’s P/B ratio is 1.25 against an industry median of 1.86 and average of 2.47 across 135 companies, with a broad range from -12.81 to 16.24. On profitability, ROE of 10.71% is slightly above the industry median of 10.49% and clearly above the average of 8.10%. ROCE of 13.24% is marginally above the median of 12.97%, though below the average of 15.53%. This paints a mixed but constructive picture: valuation is below benchmark medians, while core return metrics are around or above the industry middle.

Size is another useful lens. Gennex Laboratories has a market capitalisation of Rs 285.95 crore, above the benchmark median of Rs 138.88 crore but below the average of Rs 491.05 crore. Within an industry range of Rs 5.94 crore to Rs 2,803.21 crore, it sits in the lower-to-middle part of the listed spectrum. For readers following Gennex Laboratories Share Price Today on Univest, that combination of smaller size, lower valuation multiples and positive return ratios explains why the stock can attract attention when price action turns strong.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,803.21	50.55	1.94	-0.78	8.31
Dishman Carbogen Amcis Ltd.	DCAL	2,700.59	166.73	0.41	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,668.21	61.53	9.73	18.65	22.17
Solara Active Pharma Sciences Ltd.	SOLARA	2,653.3	0	2.41	17.23	15.34
Hikal Ltd.	HIKAL	2,644.18	0	2.2	15.22	16.15

Gennex Laboratories Ltd. (GENNE) has a P/E ratio of 14.66x compared with the displayed peer median of 50.55x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 10.71% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 13.24% versus the displayed peer median of 15.34%, providing a capital-efficiency comparison. Gennex Laboratories Ltd. (GENNE) has a market capitalisation of Rs 285.95 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Gennex Laboratories Share Price also becomes more meaningful when compared with specific listed peers in the Pharmaceuticals & Drugs space. Against Ind-Swift Laboratories, which trades at a P/E of 50.55 and P/B of 1.94 with ROE of -0.78% and ROCE of 8.31%, Gennex looks lower valued on both earnings and book value while also showing better return ratios. Ind-Swift’s market capitalisation of Rs 2,803.21 crore is far larger, but that size difference has not translated into stronger reported return metrics in the supplied snapshot.

Dishman Carbogen Amcis offers another contrast. Its P/E is 166.73 and P/B is 0.41, while ROE is -2.89% and ROCE is -0.26%, with market capitalisation at Rs 2,700.59 crore. Versus that profile, Gennex Laboratories Share Price appears to be backed by a more moderate earnings multiple and positive returns, though Dishman trades at a lower book multiple.

Beta Drugs represents a different peer profile altogether. It carries a P/E of 61.53, P/B of 9.73, ROE of 18.65% and ROCE of 22.17%, with market capitalisation of Rs 2,668.21 crore. Here, the market is assigning a much richer valuation, and the stronger profitability partly explains that difference. Gennex therefore looks cheaper, but also less profitable on return metrics.

Among mid-range comparisons, Venus Remedies trades at a P/E of 20.29 and P/B of 3.43 with ROE of 9.85% and ROCE of 7.89%, while Hester Biosciences trades at a P/E of 15.03 and P/B of 4.50 with ROE of 16.17% and ROCE of 14.12%. Compared with these names, Gennex Laboratories sits close to Hester on P/E, below both on P/B, above Venus on ROE and ROCE, and below Hester on profitability. That makes the stock’s current profile relatively balanced: lower valuation than several peers, positive returns, and a much smaller market cap than every peer listed in the supplied comparison set.

Why Investors Are Watching Gennex Laboratories

Gennex Laboratories Share Price is in focus because today’s move combined a double-digit gain with active BSE participation and a valuation profile that looks lower than much of the same-industry benchmark. For investors scanning Stocks in News, the interest lies not just in the one-day move but in how that move interacts with fundamentals, sector benchmarks and peer positioning.

• Verified price action: the stock rose 10.09% to Rs 12.88 from Rs 11.70, after trading between Rs 11.32 and Rs 12.89.
• Volume participation: BSE volume stood at 28,87,678 shares with turnover of Rs 3.72 crore.
• Market-cap context: at Rs 285.95 crore, the company remains a micro cap name within the listed Healthcare universe.
• Valuation context: P/E of 14.66 and P/B of 1.25 sit below the industry median values of 25.39 and 1.86.
• Profitability context: ROE of 10.71% is above the industry median of 10.49%, while ROCE of 13.24% is slightly above the median of 12.97%.

What should investors monitor next? The practical focus is whether Gennex Laboratories Share Price sustains attention after today’s sharp move, and whether future market updates continue to show support from valuation, profitability and relative industry positioning. Univest readers tracking Market Movers will also watch how the stock behaves against its peer set after entering today’s top gainer conversation.

About Gennex Laboratories

Gennex Laboratories Ltd. is classified within the Healthcare sector and the Pharmaceuticals & Drugs industry. That industry grouping is important because it determines the benchmark used to evaluate the company’s valuation, profitability and relative size within the listed market. In other words, the most relevant lens for Gennex Laboratories Share Price is not the broader market alone, but its standing inside the pharmaceuticals universe.

The supplied industry benchmark covers 136 companies, which indicates that Gennex operates in a broad and actively tracked listed segment. Within that universe, the company’s market capitalisation of Rs 285.95 crore places it above the industry median size of Rs 138.88 crore but below the average of Rs 491.05 crore. This suggests that it is neither among the very smallest names in the group nor among the dominant larger players.

Because the verified data here is concentrated on market, valuation and sector metrics, the clearest company-level takeaway is that Gennex Laboratories is being assessed by investors as a smaller listed pharma business with positive profitability ratios and relatively moderate valuation multiples. For anyone following Gennex Laboratories Stock News, that makes industry comparison especially important, since the stock’s market interest today is rooted as much in relative positioning as in the single-day price rise itself. Univest will typically place such stocks in the context of sector benchmarks, peer ratios and market-cap category rather than price movement alone.

Track Gennex Laboratories Share Price on Univest

Use Gennex Laboratories Ltd. (GENNE) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors who want to follow Gennex Laboratories Share Price more closely can use Univest to track live share price moves, daily percentage change, 52-week levels, valuation ratios and broader market insights in one place. For a stock like this, where today’s rise has brought fresh attention, it helps to watch not only the latest price but also P/E, P/B, ROE, ROCE, market capitalisation and peer positioning over time.

Univest also helps users monitor how Gennex Laboratories Share Price Today compares with sector benchmarks, top gainers lists and other stocks rising today in the Indian stock market. That kind of integrated market update is useful when a micro cap name moves sharply and investors want a cleaner framework for ongoing stock analysis without relying on price alone.

Frequently Asked Questions

Why is Gennex Laboratories Share Price in focus today?

Ans. Gennex Laboratories Share Price is in focus because the stock rose 10.09% in a single session to Rs 12.88 from Rs 11.70. The move placed the micro cap Healthcare stock among notable gainers tracked in today’s market action.

What was Gennex Laboratories Share Price Today?

Ans. Gennex Laboratories Share Price Today was Rs 12.88 at the time of the article. The stock opened at Rs 11.77, touched a high of Rs 12.89 and a low of Rs 11.32 during the trading session on BSE.

How much did Gennex Laboratories shares rise today?

Ans. Gennex Laboratories shares rose by Rs 1.18 today, which translates into a 10.09% gain over the previous close of Rs 11.70. That is a strong same-day move for a stock with a market capitalisation of Rs 285.95 crore.

What does today’s trading volume show for Gennex Laboratories?

Ans. The stock recorded BSE volume of 28,87,678 shares, with total volume reported at the same level and turnover of Rs 3.72 crore. This indicates that today’s Gennex Laboratories Share Price rise was accompanied by visible market participation.

What is the market capitalisation of Gennex Laboratories?

Ans. Gennex Laboratories has a market capitalisation of Rs 285.95 crore based on the supplied data. That places the company in the Micro Cap category, which is relevant when assessing the scale and visibility of today’s 10.09% share price gain.

Is Gennex Laboratories expensive based on its P/E ratio?

Ans. Gennex Laboratories trades at a P/E ratio of 14.66, which is below the Pharmaceuticals & Drugs industry median of 25.39 and average of 39.57. On supplied benchmark data, its earnings valuation appears lower than the broader same-industry set.

How does Gennex Laboratories compare on P/B ratio?

Ans. The company’s P/B ratio is 1.25, compared with the same-industry median of 1.86 and average of 2.47. That means Gennex Laboratories Share Price is trading at a lower book-value multiple than the benchmark on the supplied figures.

What do ROE and ROCE indicate for Gennex Laboratories?

Ans. Gennex Laboratories reports ROE of 10.71% and ROCE of 13.24%. ROE is slightly above the industry median of 10.49%, while ROCE is slightly above the median of 12.97%, suggesting positive profitability relative to benchmark midpoints.

What is the EPS and dividend yield of Gennex Laboratories?

Ans. The supplied data shows EPS of Rs 0.80 and a dividend yield of 0 for Gennex Laboratories. EPS links the share price to earnings through the P/E ratio, while the dividend data indicates no current yield component here.

How does Gennex Laboratories compare with listed pharma peers?

Ans. Compared with peers such as Ind-Swift Laboratories, Beta Drugs, Venus Remedies and Hester Biosciences, Gennex Laboratories has a much smaller market cap but a lower P/E than several names, with positive ROE and ROCE in the supplied peer set.